Charles Farthing

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Richard A. Koup, Jeffrey T. Safrit, Yaming Cao et al. · Journal of Virology · 1994 · 2.5K citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Edwin DeJesus, Daniel Berger, Martin Markowitz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 269 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN

R. Cheingsong‐Popov, Richard Weiss, Angus Dalgleish et al. · The Lancet · 1984 · 229 citations

Life Sciences, Immunology, Infectious Diseases +7

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

D. William Cameron, Anthony J. Japour, Yi Xu et al. · AIDS · 1999 · 198 citations

Pharmacy, Pharmacology, Pharmacotherapy +15